Pyridobenzodiazepines: a novel class of orally active, vasopressin V2 receptor selective agonists.
Our efforts in seeking low molecular weight agonists of the antidiuretic peptide hormone arginine vasopressin (AVP) have led to the identification of the clinical candidate WAY-151932 (VNA-932). Further exploration of the structural requirements for agonist activity has provided another class of potent, orally active, non-peptidic vasopressin V2 receptor selective agonists exemplified by the 5,11-dihydro-pyrido[2,3-b][1,5]benzodiazepine as a candidate for further development.
Failli
Amedeo A
AA
Chemical and Screening Sciences, Wyeth Research, CN 8000, Princeton, NJ 08543-8000, USA. faillia@wyeth.com
Shumsky
Jay S
JS
Steffan
Robert J
RJ
Caggiano
Thomas J
TJ
Williams
David K
DK
Trybulski
Eugene J
EJ
Ning
Xiaoping
X
Lock
Yeungwai
Y
Tanikella
Tarak
T
Hartmann
David
D
Chan
Peter S
PS
Park
C H
CH
D000284:Administration, Oral; D000818:Animals; D001552:Benzazepines / Q000008:administration & dosage; D001569:Benzodiazepines / Q000008:administration & dosage / Q000145:classification* / Q000494:pharmacology*; D004353:Drug Evaluation, Preclinical; D015394:Molecular Structure; D008970:Molecular Weight; D051381:Rats; D017207:Rats, Sprague-Dawley; D017483:Receptors, Vasopressin / Q000819:agonists*; D013329:Structure-Activity Relationship
C509747:5,11-dihydro-pyrido(2,3-b)(1,5)benzodiazepine; D001552:Benzazepines; D017483:Receptors, Vasopressin; C509746:WAY-151932; D001569:Benzodiazepines